26530-20-1
CAS 26530-20-1
26530-20-1 (CAS 26530-20-1) is a pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 22958.221487603303 nM | 108 | - |
| - | IC50 | 25555.428571428572 nM | 7 | - |
| - | AC50 | 760 nM | 2 | - |
| - | EC50 | 6558 nM | 2 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| OCTHILINONE | 1362738 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 26530-20-1 used for in pharmaceutical contexts?
26530-20-1 (CAS 26530-20-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 26530-20-1?
No adverse-event association or SIDER side-effect rows are rendered for 26530-20-1 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 26530-20-1 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for OCTYLISOTHIAZOLINONE with EU status "permitted".
What clinical phase is 26530-20-1 in?
No phase 1-4 clinical development badge is rendered for 26530-20-1 because the matched compound identifier rows do not contain a max-phase value.